Gene therapy study for OTOF-related hearing loss
Part of Brain & nervous system, Ear, nose & throat clinical trials.
This trial tests a one-time gene therapy delivered into the ear to improve hearing in people with certain OTOF gene changes. It studies safety and how well the treatment can work, especially in children and infants, as doctors monitor hearing tests for up to 48 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child’s parent/guardian) agree to sign consent and follow the study plan
- You agree to gene testing to confirm the participant has OTOF-related genetic hearing loss
- You agree to age-appropriate vaccinations, as the study requires
- The study can do the needed hearing and other checkup tests at screening
- Genetic testing must show two bad (likely) OTOF gene changes (biallelic pathogenic/likely pathogenic)
- The ear to be treated must have exam results showing the outer hair cells are still working
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called ECUR-506 for baby boys under 9 months old with a severe form of OTC deficiency. The goal is to see if it can help their bodies process ammonia better, reducing the need for a strict protein-restricted diet and medications.
This trial tests a gene therapy called EH002 for people with severe or profound hearing loss due to changes in the OTOF gene. The treatment aims to help the ear hear better by replacing the faulty gene.
This trial tests an injection called EHT102 for children who have severe or profound hearing loss due to mutations in the Otoferlin gene. The goal is to see if the treatment can restore or improve hearing.
This early-stage study tests a one-time gene therapy to help patients with profound hearing loss linked to otoferlin gene mutations. It may help hearing by delivering a working version of the otoferlin gene to the inner ear, followed by long-term monitoring.
This study follows up with people who received a gene therapy (AAVAnc80-hOTOF) in a previous clinical trial. It checks how well the treatment works over time and how safe it is.
This study follows children with hearing loss caused by changes in specific genes (GJB2 or OTOF). It helps researchers understand how hearing develops over time and how children may do with or without cochlear implants.
Hear when a new Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.